<DOC>
	<DOCNO>NCT02320773</DOCNO>
	<brief_summary>A study understand impact Betmiga® patient quality life , satisfaction treatment , long patient remain treatment , pattern healthcare resource utilisation , safety prescribe physician routine clinical practice .</brief_summary>
	<brief_title>A Prospective Non-interventional Study Overactive Bladder ( OAB ) Patients Prescribed Betmiga® Part Routine Clinical Practice</brief_title>
	<detailed_description>Single arm , hybrid model study , observe patient Betmiga condition routine clinical practice , element retrospective data collection 2 year prior enrolment study</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients diagnose OAB symptom Visit 1 study . OAB define International Urogynecological Association ( IUGA ) /International Continence Society ( ICS ) 2010 joint report urinary urgency , without urinary incontinence , usually frequency nocturia , proven infection obvious pathology . Patients whose physician make decision prescribe Betmiga® part routine clinical practice start treatment . Patients currently take Betmiga® . Contraindication ( ) per Betmiga® Summary Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Betanis®</keyword>
	<keyword>Betmiga®</keyword>
	<keyword>Observational</keyword>
	<keyword>Myrbetriq®</keyword>
</DOC>